Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis.
INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 102.5K |
| Three Month Average Volume | 3.8M |
| High Low | |
| Fifty-Two Week High | 18.95 USD |
| Fifty-Two Week Low | 10.8 USD |
| Fifty-Two Week High Date | 05 Jun 2024 |
| Fifty-Two Week Low Date | 12 Aug 2024 |
| Price and Volume | |
| Current Price | 14.56 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.15% |
| Thirteen Week Relative Price Change | -16.28% |
| Twenty-Six Week Relative Price Change | -99,999.99% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -99,999.99% |
| Price Change | |
| One Day Price Change | 4.67% |
| Thirteen Week Price Change | -10.40% |
| Twenty-Six Week Price Change | -99,999.99% |
| Five Day Price Change | 9.15% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -99,999.99% |
| Month-to-Date Price Change | 0.34% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.91838 USD |
| Book Value Per Share (Most Recent Quarter) | 15.15388 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.91838 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 15.15388 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -8.61316 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.03819 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.04344 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.12118 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 121.2109 USD |
| Normalized (Last Fiscal Year) | -5.12118 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.12118 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 122.8246 USD |
| Including Extraordinary Items (Last Fiscal Year) | -5.12118 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 121.2109 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 5.86715 USD |
| Cash Per Share (Most Recent Quarter) | 15.67156 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.06123 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 38.37654 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -5.58098 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,282 |
| Cash Flow Revenue (Trailing Twelve Months) | -12,847 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 88,264.55% |
| Pretax Margin (Last Fiscal Year) | -13,318.00% |
| Pretax Margin (5 Year) | -1,588.47% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -12,178.94% |
| Operating Margin (Trailing Twelve Months) | 89,188.29% |
| Operating Margin (5 Year) | -1,436.31% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -13,318.17% |
| Net Profit Margin (Trailing Twelve Months) | 88,264.55% |
| Net Profit Margin (5 Year) | -1,590.91% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 233.33% |
| Revenue Growth (3 Year) | -26.85% |
| Revenue Change (Trailing Twelve Months) | 209.35% |
| Revenue Per Share Growth | -30.44% |
| Revenue Growth (5 Year) | -48.12% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 26.30% |
| Total Debt (5 Year) | 85.22% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 11,738.74% |
| EPS Change (Trailing Twelve Months) | 3,093.10% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -226,860,000 |
| Net Debt (Last Fiscal Year) | -70,956,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 117 |
| Price to Sales (Trailing Twelve Months) | 114 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 0 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 0 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 16 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 476 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 0 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -197,902,000 |
| Free Cash Flow (Trailing Twelve Months) | -238,061,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -11 |
| Net Interest Coverage (Trailing Twelve Months) | -22 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 476 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -80.07% |
| Return on Assets (Trailing Twelve Months) | 693.63% |
| Return on Assets (5 Year) | -77.06% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -475.31% |
| Return on Equity (Trailing Twelve Months) | 1,679.65% |
| Return on Equity (5 Year) | -698.78% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -93.12% |
| Return on Investment (Trailing Twelve Months) | 815.31% |
| Return on Investment (5 Year) | -93.91% |